Arrowhead to Present at Rodman and Renshaw Annual Global Investment Conference

PASADENA, Calif. — September 5, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its President and Chief Executive Officer, Dr. Chris Anzalone, is presenting at the Rodman and Renshaw Annual Global Investment Conference on Monday September 10^that the Waldorf Astoria in New York City. Dr. Anzalone will present a company overview at 10:50 AM Eastern time and will be part of a panel discussion titled, “Obesity: Dawn of a New Era of Pharmacologic Therapy,” at 12:30 PM.

A live webcast of the company overview presentation can be accessed by visiting the News & Events section of the company’s website, http://www.arrowheadresearch.com/presentations.  A replay will also be archived on the website and available for 60 days.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and infectious disease. The company leverages its platform technologies to design and develop peptide-drug conjugates (PDCs) which specifically home to cell types of interest while sparing off-target tissues, creates targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and works with partners to create improved versions of traditional small molecule drugs.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to ir@arrowres.com